Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04847544 | A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19. | PHASE2 | COMPLETED | 11 | — | — | Mar 31, 2021 | Oct 15, 2021 | Feb 17, 2025 | 1 | United States |
Safety was assessed through serious adverse event reporting.
| Arm | Type | Description |
|---|---|---|
| ADX-629 300 mg administered orally twice daily (BID) for up to 28 days. | EXPERIMENTAL | - |
| Placebo administered orally BID for up to 28 days. | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ADX-629 | DRUG | ADX-629 administered orally twice daily (BID) for up to 28 days. |
| Placebo | DRUG | Placebo administered orally BID for up to 28 days. |
Inclusion Criteria: * Is a male or female greater than or equal to18 years of age at Screening; * Is willing and able to sign and date (or has a legally authorized representative willing to sign and date) a written (or electronic) informed consent form or provide equivalent consent per Food and Dru...